BCM
SLDB icon

Bridgeway Capital Management’s Solid Biosciences SLDB Stock Holding History

Bridgeway Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,460
Closed -$169K – 1305
2026
Q1 		$169K Hold
23,460
– – ﹤0.01% 1063
2025
Q4 		$132K Sell
23,460
-15,000
-39% -$81.3K ﹤0.01% 1090
2025
Q3 		$237K Sell
38,460
-60,071
-61% -$351K 0.01% 981
2025
Q2 		$480K Buy
98,531
+15,000
+18% +$53K 0.01% 784
2025
Q1 		$309K Sell
83,531
-19,100
-19% -$81.8K 0.01% 835
2024
Q4 		$411K Buy
102,631
+51,574
+101% +$283K 0.01% 856
2024
Q3 		$356K Hold
51,057
– – 0.01% 942
2024
Q2 		$289K Hold
51,057
– – 0.01% 973
2024
Q1 		$680K Hold
51,057
– – 0.01% 837
2023
Q4 		$313K Buy
51,057
+15,000
+42% +$48K 0.01% 1058
2023
Q3 		$90.9K Buy
36,057
+10,000
+38% +$38.8K ﹤0.01% 1244
2023
Q2 		$137K Sell
26,057
-8,629
-25% -$48.6K ﹤0.01% 1208
2023
Q1 		$164K Buy
34,686
+15,000
+76% +$90.1K ﹤0.01% 1136
2022
Q4 		$106K Sell
19,686
-1
-0% -$7 ﹤0.01% 1206
2022
Q3 		$138K Hold
19,687
– – ﹤0.01% 1216
2022
Q2 		$182K Sell
19,687
-6,666
-25% -$69.3K ﹤0.01% 1109
2022
Q1 		$474K Buy
26,353
+13,333
+102% +$235K 0.01% 950
2021
Q4 		$342K Buy
13,020
+10,587
+435% +$324K 0.01% 1070
2021
Q3 		$87K Sell
2,433
-6,127
-72% -$260K ﹤0.01% 1258
2021
Q2 		$470K Sell
8,560
-3,132
-27% -$207K 0.01% 1083
2021
Q1 		$970K Hold
11,692
– – 0.02% 874
2020
Q4 		$1.33M Sell
11,692
-3,066
-21% -$194K 0.03% 675
2020
Q3 		$449K Buy
14,758
+5,333
+57% +$204K 0.01% 939
2020
Q2 		$414K Buy
9,425
+5,560
+144% +$231K 0.01% 921
2020
Q1 		$139K Buy
3,865
+798
+26% +$39.5K ﹤0.01% 1136
2019
Q4 		$205K Hold
3,067
– – ﹤0.01% 1194
2019
Q3 		$476K Buy
+3,067
New +$347K 0.01% 976

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bridgeway Capital Management's SLDB Position: Q2 2026 in Review

Bridgeway Capital Management sold out of Solid Biosciences (SLDB) in Q2 2026, closing a stake of 23,460 shares — an estimated $169K sold.

Bridgeway Capital Management first reported a position in SLDB in Q3 2019 and held it in 27 quarters. The position peaked at $1.33M in Q4 2020. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Bridgeway Capital Management reported no remaining Solid Biosciences position as of Q2 2026 after selling out during the quarter.
  • Bridgeway Capital Management sold 23,460 Solid Biosciences shares in Q2 2026, an estimated $169K.
  • Bridgeway Capital Management first reported a position in Solid Biosciences in Q3 2019 and held it in 27 quarters.
  • Bridgeway Capital Management's Solid Biosciences position peaked at $1.33M in Q4 2020.
  • 157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.